Q-omics provides the consensus-scored MTCYBP44 profile across patient tissues and cancer cell-line models. MTCYBP44 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MTCYBP44 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, MTCYBP44 RNA expression shows 6,778 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, PRAD, and GBM as cancer lineages where MTCYBP44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCYBP44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCYBP44 survival associations across molecular data types. MTCYBP44 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCYBP44 RNA expression–survival associations across cancer types. High MTCYBP44 expression shows unfavorable associations in MESO, STAD, PAAD, KIRC, KICH and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MTCYBP44 RNA expression.
This table summarizes MTCYBP44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for MTCYBP44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCYBP44 shows higher tumor expression in PRAD. The PRAD box plot shows higher MTCYBP44 RNA expression in tumor versus normal tissue (log2 FC = +0.010, t-test p = .048).
This table shows molecular features associated with MTCYBP44 in patient tissues and cancer cell lines. In patient samples, MTCYBP44 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
